OmniBioMed

The mission of OmniBioMed is to profitably commercialize late research-stage biomedical technologies that have the power to cure disease, relieve suffering, extend life, or otherwise improve the human condition.

OmniBioMed’s Focus

Human Therapeutics ResearchHuman Therapeutics Research Anti-Autism Technology Anti-Autism Technology Selective Panning Process™ Selective Panning Process™

Biomolecule ManufacturingBiomolecule Manufacturing Human Plasma-Derived BiomoleculesHuman Plasma-Derived Biomolecules Bacteria-Derived Proteins and Bacteria-Derived Proteins and

EnzymesEnzymes Value-Added ProductsValue-Added Products

Two Means To One End

Utah State University Autism ProjectUtah State University Autism Project (Pat. in (Pat. in Preparation)Preparation) Treat Autism at the Molecular Level Treat Autism at the Molecular Level Treat Attention Deficit Hyperactive Disorder (ADHD)Treat Attention Deficit Hyperactive Disorder (ADHD)

Selective Panning ProcessSelective Panning Process™ ™ (Pat. No. 6,056,951)(Pat. No. 6,056,951) Remove Graft vs Host Disease from Bone Marrow Remove Graft vs Host Disease from Bone Marrow

TransplantsTransplants Prevent Organ Transplant RejectionPrevent Organ Transplant Rejection Methods to Treat Specific Forms of CancerMethods to Treat Specific Forms of Cancer

Human Therapeutics Research

Anti-Autism Technology

DDr. Anthony R. Torres, M.D., r. Anthony R. Torres, M.D., Director of the Immunogenetics Director of the Immunogenetics Laboratory at Utah State Laboratory at Utah State University, recently proposed a University, recently proposed a novel theory regarding the novel theory regarding the cause of autism which may cause of autism which may eventually lead to its cure.eventually lead to its cure.

AAutism research at USU’s utism research at USU’s Center For Persons With Center For Persons With Disabilities has been ongoing for Disabilities has been ongoing for over 15 years, supported by over 15 years, supported by grants from the National grants from the National Institutes of Health (NIH) and Institutes of Health (NIH) and Cure Autism Now (CAN).Cure Autism Now (CAN).

Selective Panning Process™

SSelective Panning is a elective Panning is a patented therapeutic patented therapeutic technology, invented and technology, invented and wholly owned by Dr. Torres. It wholly owned by Dr. Torres. It is designed to counteract the is designed to counteract the effects of auto-immune effects of auto-immune disorders such as Graft vs disorders such as Graft vs Host Disease, which kills Host Disease, which kills about 50% of all bone marrow about 50% of all bone marrow transplant recipients within transplant recipients within five years of receiving five years of receiving treatment.treatment.

FFuture applications may also uture applications may also combat organ transplant combat organ transplant rejection (Host vs Graft rejection (Host vs Graft Disease), and lead to Disease), and lead to treatments that target certain treatments that target certain forms of cancer. forms of cancer.

Summary: Human Therapeutics

The primary goal of OmniBioMed’s human therapeutic The primary goal of OmniBioMed’s human therapeutic research is to develop data that proves feasibility.research is to develop data that proves feasibility.

Once sufficient data is developed, OmniBioMed will Once sufficient data is developed, OmniBioMed will aggressively seek pharmaceutical partners to aggressively seek pharmaceutical partners to participate in further research and FDA clinical trials.participate in further research and FDA clinical trials.

OmniBioMed will also explore the practicability of OmniBioMed will also explore the practicability of building an FDA-approved manufacturing facility to building an FDA-approved manufacturing facility to produce proprietary therapeutic agents, as well as produce proprietary therapeutic agents, as well as certain natural biomedical molecules and their value-certain natural biomedical molecules and their value-added products.added products.

Biomolecule Manufacturing

Over 20 Specialty Biomedical Over 20 Specialty Biomedical Products, Used For:Products, Used For:

Cell CultureCell Culture Tissue EngineeringTissue Engineering ImmunodiagnosticsImmunodiagnostics Affinity ChromatographyAffinity Chromatography

Biomolecules From Human Blood

OmniBioMed has pre-existing OmniBioMed has pre-existing technology to extract and purify technology to extract and purify several products from human several products from human plasma, including:plasma, including:

Transferrin, fibronectin, thrombin, Transferrin, fibronectin, thrombin, vitronectin, thyroxin binding vitronectin, thyroxin binding globulin, and others.globulin, and others.

Immunoglobulins: IgG, IgA, IgM, Immunoglobulins: IgG, IgA, IgM, etc.etc.

Human A-Gamma Serum™Human A-Gamma Serum™

HHuman plasma biomolecules will uman plasma biomolecules will be manufactured and marketed be manufactured and marketed worldwide under an agreement worldwide under an agreement with SeraCare Life Sciences, Inc., with SeraCare Life Sciences, Inc., using OmniBioMed technology.using OmniBioMed technology.

Electron micrograph of a human lymphocyte surrounded by red corpuscles.

An important source of near-term revenues

Cell Culture

Human plasma-based cell culture Human plasma-based cell culture products are the wave of the future, products are the wave of the future, since products based upon fetal bovine since products based upon fetal bovine serum may contain contaminants like serum may contain contaminants like Mad Cow Disease.Mad Cow Disease.

OmniBioMed has several ways OmniBioMed has several ways to meet this challenge and to meet this challenge and capture an expanding market-capture an expanding market-share.share.

Human plasma proteinsHuman plasma proteins Human plasma-based cell Human plasma-based cell

culture fluidsculture fluids Proprietary ion exchange Proprietary ion exchange

chromatography methodschromatography methods Bacteria-derived proteins Bacteria-derived proteins

and enzymesand enzymes

Tissue Engineering

OmniBioMed’s TEAMolecules™ after 5 days growth

Grown in Omni’s proprietary human serum-based tissue

culture fluid

Grown in a commercial fetal bovine serum-based tissue

culture fluid

OmniBioMed’s TEAMolecules™, and proprietary culture fluids, support rapid multi-layer growth of medically important human cell lines, such as collagen and liver cells.

Biomolecules From Bacteria

Human- and Animal-Free Protein A™

Important Enzymes Lipase

PenicillinaseInterotoxin B

AvidinStreptavidin

Affinity Chromatography

HHuman- and Animal-Free Protein A™ (Patent pending)uman- and Animal-Free Protein A™ (Patent pending)

Natural extracellular Natural extracellular StaphylococcalStaphylococcal Protein A Protein A World’s safest source of natural Protein AWorld’s safest source of natural Protein A Superior human antibody binding characteristicsSuperior human antibody binding characteristics Ideal for therapeutic processing of monoclonal antibodiesIdeal for therapeutic processing of monoclonal antibodies

Therapeutic monoclonal antibodies such Rituxan®, co-developed by Genentech and IDEC to fight Non-Hodgkin’s Lymphoma, are purified on Protein A. OmniBioMed’s Protein A is the only natural source that cannot possibly contain contaminants such as AIDS envelope proteins or Mad Cow Disease.

Summary: Biomolecule Mfg.

Molecules From Human PlasmaMolecules From Human Plasma Transferrin, fibronectin, Thrombin, Immunoglobulins, Transferrin, fibronectin, Thrombin, Immunoglobulins,

etc.etc. TEAMolecules™ for tissue engineering (patent TEAMolecules™ for tissue engineering (patent

pending)pending)

Molecules From Bacterial SourcesMolecules From Bacterial Sources Protein A (patent pending), protein G, avidin, etc.Protein A (patent pending), protein G, avidin, etc. Enzymes such as lipase, penicillinase, interotoxin BEnzymes such as lipase, penicillinase, interotoxin B

Value-Added Products Derived From Human Value-Added Products Derived From Human Plasma and Bacterial ProteinsPlasma and Bacterial Proteins Proprietary cell culture and tissue engineering Proprietary cell culture and tissue engineering

nutrient solutionsnutrient solutions Chromatography resins and magnetic microspheresChromatography resins and magnetic microspheres Immunodiagnostic reagents and molecular probesImmunodiagnostic reagents and molecular probes

Important Strategic Alliances

OmniBioMed has reached OmniBioMed has reached key agreements with:key agreements with:

The Utah State UniversityThe Utah State University SeraCare, Inc. (AMEX “SRK”)SeraCare, Inc. (AMEX “SRK”)

These important alliances will These important alliances will accelerate autism research, and accelerate autism research, and simultaneously jumpstart simultaneously jumpstart OmniBioMed’s short-term revenue-OmniBioMed’s short-term revenue-producing operations with a producing operations with a research laboratory in place, and a research laboratory in place, and a well-entrenched corporate partner well-entrenched corporate partner ready to market and manufacture ready to market and manufacture several of OmniBioMed’s biomedical several of OmniBioMed’s biomedical products in their FDA-approved products in their FDA-approved facility.facility.

OmniBioMed™ Technologies

OmniBioMed has licensed, or has agreements to OmniBioMed has licensed, or has agreements to license, the following intellectual properties:license, the following intellectual properties:

Treatments for Autism and ADHD Treatments for Autism and ADHD Patent in preparation Patent in preparation Selective Panning Process™ Selective Panning Process™ US Pat. No. 6,056,951 US Pat. No. 6,056,951 Human transferrin, thrombin, etc. Trade secret processesHuman transferrin, thrombin, etc. Trade secret processes Antibody purification technologyAntibody purification technology US Pat. No. 5,028,696 US Pat. No. 5,028,696 Human plasma-based culture fluids Trade secret formulasHuman plasma-based culture fluids Trade secret formulas A-Gamma Human Serum™A-Gamma Human Serum™ Trade secret process Trade secret process TEAMolecules™ attachment proteinsTEAMolecules™ attachment proteins Provisional patent Provisional patent

pendingpending Human- and Animal-Free Protein A™Human- and Animal-Free Protein A™ Pat. App. No. 60/056786 Pat. App. No. 60/056786

Additional patents will be applied for during Year-1 to protect proprietary technologies.

OmniBioMed™

AA startup enterprise built upon a startup enterprise built upon a mountain of technology, guided mountain of technology, guided by decades of scientific expertise by decades of scientific expertise and entrepreneurial experience.and entrepreneurial experience.

OmniBioMed™

AA novel business model that reduces novel business model that reduces the financial risks inherently the financial risks inherently associated with developing human associated with developing human therapeutic products. therapeutic products.

OOmniBioMed will accomplish this by mniBioMed will accomplish this by generating revenues derived from generating revenues derived from manufacturing superior products that manufacturing superior products that are widely used by the industry it are widely used by the industry it serves.serves.

OmniBioMed™

SStrategic alliances, already trategic alliances, already formed, ensure OmniBioMed formed, ensure OmniBioMed

will begin generating revenues will begin generating revenues within six months of receiving within six months of receiving

its angel/seed money its angel/seed money financing.financing.

OmniBioMed™

WWill raise $500,000 from ill raise $500,000 from qualified investors to grow the qualified investors to grow the business and launch its initial business and launch its initial

products, plus an additional $2 products, plus an additional $2 million in Year-1 to expand its million in Year-1 to expand its proprietary product lines and proprietary product lines and

capture market-share.capture market-share.

Additional Information

To receive a current business plan, contact:

Walt RunkisVoice: +1 203.445.9975Cell: +1 203.521.7943

Email: walt@omnibiomed.com